Eastern States Residency Conference Dosing of Methadone in the Palliative Care Setting Samantha Bryant, Pharm.D., BCPS PGY2 Drug Information Resident Robert.

Slides:



Advertisements
Similar presentations
Opioids and other drugs we use on palliative care
Advertisements

GENERAL PHARMACOLOGY.
Opioid Pharmacology: How to choose and how to use Romayne Gallagher MD, CCFP Division of Palliative Providence Health Care.
 The term narcotic is used for the sedative agent, For pain control medications of both narcotic and non- narcotic varieties. Today, the term "narcotic"
CANCER PAIN MANAGEMENT PAMELA M. SUTTON, M.D. FAAHPM DECEMBER 2013.
Medication Assisted Treatment Michael Palladini, RPh MBA CAC
Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.
Key dosing points: Begin a bowel regimen when opioid therapy is initiated (senna + docusate). For CHRONIC pain, use a scheduled medication regimen. ( ex:
Calvin Lui, MD PGY2 February 8,  Common Opioid Agents and Good Starting Dosages  Opioid Conversion  Use of Patient Controlled Analgesia and Good.
Sublingual Buprenorphine and Pain
1 F ‘08 P. Andrews, Instructor. 2 We’ll talk about  Buprenex  Stadol  Vicodin  Demerol  Morphine sulfate  Fentanyl  Nubain  Trexan  Narcan 3.
Fentanyl. Fentanyl Basics  First synthesized in Belgium in the 1950’s for anesthesia  Trade Name “Sublimaze”  It is a potent synthetic narcotic with.
Methadone By: Heidi Smith. Drug Name Information  Street Names  Brand Name  Chemical Name Frizzies Dollies Dolophine Methadone Hydrochloride.
OPIOIDS NIRALI PATEL (2009) Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 7 Opioid (Narcotic) Analgesics and Antagonists.
BASIC PHARMACOLOGY Generic Brand Name. Objectives Categories Label Terminology Abbrevi- ations Law Administra- tion Conversions Dosage.
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.
Assessing Pain What is pain? Do you believe that “perception is reality”? What are EB clinical practice guidelines?? What if client non-verbal, or you.
August 16, 2015 Equianalgesia Opioid Calculator: JHH Applications Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management Department.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
How and Why Drugs Work Chapter 5
Use of the Personal Therapy Manager With Prialt® (Ziconotide Intrathecal Infusion) for Patient-controlled Analgesia: Case Series Gladstone C. McDowell,
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 28 Opioid (Narcotic) Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Step two: Moderate pain Tramadol Opioid combinations Acetaminophen or aspirin with Codeine Hydrocodone Oxycodone Plus/minus adjuvants Dose limiting toxicity.
Prepared by : Areen Zraikah Dana Fatayer. Pharmacology: Naloxone and nalmefene are pure opioid antagonists that competitively block mu, kappa, and delta.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Pain Most common reason people seek health care Tissue damage activates free nerve endings (pain receptors) Generally indicates tissue damage.
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
For Pain or Not for Pain: Methadone Madness
Fundamentals of Drug Action
Opiates in Chronic Pain Dr S Vas, Barnsley VTS October 2014.
2009 Pandemic Education Package Pharmacology Review.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 8 Individual Variation in Drug Responses.
Toujeo® and it’s Place in Therapy
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 14, 2008 History of Modified-Release Morphine and Opioid/Antagonist.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Acute Pain Management Solomon Liao, M.D. Clinical Professor Director of Palliative Care Service UCI Hospitalist Program.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Aging Q3 Pain Management ACOVE  Pharmacological treatment with analgesics for pain is the most common in the elderly, however, the use of alternative medications.
1 QTc and Quinolones: recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA.
Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015
WHO Analgesic Ladder Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Treatment: other opioids Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Breakthrough, emergency, and incident pain
Side effects and toxicity of analgesics Disclaimer: This presentation contains information on the general principles of pain management. This presentation.
Addiction and dependence Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Ondansetron Tactical Combat Casualty Care Guideline Change Dec 14.
A Revolution in Pain Pharmaceuticals 1. The Problem Opioids are the oldest and most prescribed pain drugs. They are the most powerful analgesics for treatment.
Buprenorphine {Suboxone®, Subutex®}
Inadequately treated acute pain can lead to prolonged hospital stay, delayed recovery, psychological consequences, increased costs and the development.
GP Clinical Governance Meeting 13 th of July 2011 Dr Marion Lieth Consultant in Palliative Medicine, Bolton Hospital and Bolton Hospice Common issues:
Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015
COMPARISON OF ADVERSE EFFECT PROFILES OF PAIN REGIMENS WITH AND WITHOUT INTRAVENOUS ACETAMINOPHEN IN TOTAL HIP AND KNEE ARTHROPLASTY PATIENTS Alyssa J.
Medication Assisted Treatment for Opioid Use Disorders
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Dominique A. Lossignola and Cristina Dumitrescu Current Opinion in Oncology 2010, 22:302–306 R2 박소영 /prof. 이재진.
Emmeline Tran, PharmD, BCPS Medical University of South Carolina PGY2 Internal Medicine Resident.
DEBBIE DONELSON, MD Opioid use for nonmalignant pain management.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
*Risk Evaluation and Mitigation Strategy
Opiod analgesics 9월 흉부외과 인턴 김영재.
Opioids for the management chronic non-cancer pain in Primary Care:
Initiating Therapy, Modifying Dosing, and Discontinuing Use of ER/LA Opioid Analgesics Unit 2 Eric Widera, M.D.
Acute Pain Management for Patients Receiving Buprenorphine Therapy
Pharmacology of Opioids (1)
Acute Pain Management Solomon Liao, M.D.
Opioids and other drugs we use in palliative care
Pain Management: Patients Maintained on Buprenorphine
Supported in part by Arkansas Blue Cross and Blue Shield
Presentation transcript:

Eastern States Residency Conference Dosing of Methadone in the Palliative Care Setting Samantha Bryant, Pharm.D., BCPS PGY2 Drug Information Resident Robert Wood Johnson University Hospital May 2016

Disclosures There is no commercial support associated with this educational activity. Each presenter and planning committee member has disclosed no relationship with any commercial company. There will be no presentation of off-label use of any drug or medical device. 2

Objectives Describe the appropriate dosing of methadone for both opioid naïve and opioid tolerant patients List the various adverse effects that may be seen with the use of methadone 3

BACKGROUND 4 Microsoft ClipArt

What is Methadone? 5 Synthetic opioid –Agonist at the mu receptor –Antagonist at the N-methyl-D-aspartate (NMDA) receptor Indications –Treatment of opioid dependence –Treatment of moderate to severe pain in patients with life-limiting illnesses Duration of analgesic effect: 4-8 hours Half-life: up to 59 hours Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016 ]

Advantages of Methadone Efficacy Long half-life Convenient dosing schedule Low cost 6 Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19:13-24.

Disadvantages Dosing can be challenging Pharmacokinetic properties are highly variable and patient specific Sequesters in multiple body compartments Interacts with numerous other medications Conversion from other opioids to methadone is not linear 7 Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19:13-24.

Warnings November 2006, the FDA issued a Public Health Advisory: “Methadone use for pain control may result in death and life-threatening changes in breathing and heartbeat.” Other BBWs: –Addiction, abuse, misuse; accidental ingestions; neonatal opioid withdrawal syndrome; conditions for distribution and use of methadone products for the treatment of opioid addiction 8 FDA Public Health Advisory: Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat [Internet]. US Food and Drug Administration. White Oak, MD. Available from: [accessed March 11, 2016]

Adverse Effects Common –Hypotension –Diaphoresis –Constipation, Nausea, Vomiting –Asthenia, Dizziness, Lightheadedness, Sedated Serious –Decreased vascular flow, Prolonged QT interval, Torsades de pointes –Hypoglycemia –Respiratory acidosis, Respiratory arrest, Respiratory depression –Drug dependence 9 Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016] Webster LR. Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System. In: Cruciani RA, Knotkova H, editors. Handbook of Methadone Prescribing and Buprenorphine Therapy. New York: Springer; p

Question #1 Which of the following is an adverse effect that may be seen with the use of methadone? a.Constipation b.Nausea c.QTc prolongation d. Respiratory Depression e.All of the above 10

Question #1 Which of the following is an adverse effect that may be seen with the use of methadone? a.Constipation b.Nausea c.QTc prolongation d.Respiratory Depression e.All of the above 11

Opioid Naive Usual starting dose is 2.5 to 10mg PO/IV every 8-12 hours, slowly titrated to effect 12 Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016] Chou R, Fanciullo GJ, Fine PG, et al: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10(2):

Opioid Experienced/Tolerant Conversion to methadone is not linear Potency increases over time and with repeated dosing Incomplete cross-tolerance 13 Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016] Total Daily Baseline Oral Morphine Dose Estimated Daily Oral Methadone Requirement as Percent of Total Daily Morphine Dose <100 mg20-30% 100 to 300 mg10-20% 300 to 600 mg8-12% 600 to 1000 mg5-10% > 1000 mg<5%

IV to PO When converting from parenteral methadone to oral methadone, one should use a 1:2 ratio –Example: 10 mg IV methadone is equal 20 mg PO methadone 14 Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016]

End of Life NPO Patients Convert by a ratio of 1:1 oral to buccal Give desired dose using 10 mg/mL solution to oral cavity between the lower molars and buccal mucosa MAX 1.5 mL in each buccal space Hold for several minutes for transmucosal absorption and gently massage cheek 15 Spaner D. Effectiveness of the buccal mucosa route for methadone administration at the end of life. J Palliat Med 2014; 17:

Question #2 Patient AB is on Morphine 50mg ER tablets BID. Calculate the approximate starting dose of oral methadone to be given every eight hours. a.20mg TID b.15mg TID c.10mg TID d.5mg TID 16

Question #2 Patient AB is on Morphine 50mg ER tablets BID. Calculate the approximate starting dose of oral methadone to be given every three hours. a.20mg TID b.15mg TID c.10mg TID d.5mg TID 17

Take Home Points Methadone is an affordable long-acting opioid analgesic It is effective for some patients There are several serious adverse effects and drug interactions with methadone that need to be considered Unique pharmacologic properties of methadone call for caution and expertise in prescribing it 18

References 1.Dolophine Hydrochloride [Package Insert]. Columbus, OH: Roxane Laboratories, Inc Available from: [accessed March 11, 2016] 2.Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19: FDA Public Health Advisory: Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat [Internet]. US Food and Drug Administration. White Oak, MD. Available from: [accessed March 11, 2016] 4.Webster LR. Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System. In: Cruciani RA, Knotkova H, editors. Handbook of Methadone Prescribing and Buprenorphine Therapy. New York: Springer; p Chou R, Fanciullo GJ, Fine PG, et al: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10(2): Spaner D. Effectiveness of the buccal mucosa route for methadone administration at the end of life. J Palliat Med 2014; 17:

Questions? 20 Microsoft ClipArt

Eastern States Residency Conference Dosing of Methadone in the Palliative Care Setting Samantha Bryant, Pharm.D., BCPS PGY2 Drug Information Resident Robert Wood Johnson University Hospital May 2016